These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 29392371)

  • 21. Comparability of blinded remote and site-based assessments of response to adjunctive esketamine or placebo nasal spray in patients with treatment resistant depression.
    Targum SD; Daly E; Fedgchin M; Cooper K; Singh JB
    J Psychiatr Res; 2019 Apr; 111():68-73. PubMed ID: 30685564
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intranasal esketamine: A novel drug for treatment-resistant depression.
    Khorassani F; Talreja O
    Am J Health Syst Pharm; 2020 Aug; 77(17):1382-1388. PubMed ID: 32729898
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of esketamine nasal spray by sex in patients with treatment-resistant depression: findings from short-term randomized, controlled trials.
    Jones RR; Freeman MP; Kornstein SG; Cooper K; Daly EJ; Canuso CM; Nicholson S
    Arch Womens Ment Health; 2022 Apr; 25(2):313-326. PubMed ID: 34973081
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early Onset of Efficacy and Consistency of Response Across Multiple Migraine Attacks From the Randomized COMPASS Study: AVP-825 Breath Powered
    Silberstein S; Winner PK; McAllister PJ; Tepper SJ; Halker R; Mahmoud RA; Siffert J
    Headache; 2017 Jun; 57(6):862-876. PubMed ID: 28497569
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
    Feder A; Parides MK; Murrough JW; Perez AM; Morgan JE; Saxena S; Kirkwood K; Aan Het Rot M; Lapidus KA; Wan LB; Iosifescu D; Charney DS
    JAMA Psychiatry; 2014 Jun; 71(6):681-8. PubMed ID: 24740528
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomized controlled trial of intranasal ketamine in major depressive disorder.
    Lapidus KA; Levitch CF; Perez AM; Brallier JW; Parides MK; Soleimani L; Feder A; Iosifescu DV; Charney DS; Murrough JW
    Biol Psychiatry; 2014 Dec; 76(12):970-6. PubMed ID: 24821196
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: novel findings using a simulated adult workplace environment design.
    Wigal T; Brams M; Gasior M; Gao J; Squires L; Giblin J;
    Behav Brain Funct; 2010 Jun; 6():34. PubMed ID: 20576091
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early-Onset Efficacy and Safety Pilot Study of Amphetamine Extended-Release Oral Suspension in the Treatment of Children with Attention-Deficit/Hyperactivity Disorder.
    Childress AC; Kando JC; King TR; Pardo A; Herman BK
    J Child Adolesc Psychopharmacol; 2019 Feb; 29(1):2-8. PubMed ID: 30575407
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cognitive impairment after small-dose ketamine isomers in comparison to equianalgesic racemic ketamine in human volunteers.
    Pfenninger EG; Durieux ME; Himmelseher S
    Anesthesiology; 2002 Feb; 96(2):357-66. PubMed ID: 11818769
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomised, multicentre, placebo-controlled, double-blind crossover study investigating the effect of solifenacin and oxybutynin in elderly people with mild cognitive impairment: the SENIOR study.
    Wagg A; Dale M; Tretter R; Stow B; Compion G
    Eur Urol; 2013 Jul; 64(1):74-81. PubMed ID: 23332882
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomized, double-blind, placebo-controlled, crossover trial evaluating the effect of intranasal insulin on cognition and mood in individuals with treatment-resistant major depressive disorder.
    Cha DS; Best MW; Bowie CR; Gallaugher LA; Woldeyohannes HO; Soczynska JK; Lewis G; MacQueen G; Sahakian BJ; Kennedy SH; Lui JP; Mansur RB; McIntyre RS
    J Affect Disord; 2017 Mar; 210():57-65. PubMed ID: 28013123
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Double-blind crossover study of the cognitive effects of lorazepam in healthy apolipoprotein E (APOE)-epsilon4 carriers.
    Stonnington CM; Snyder PJ; Hentz JG; Reiman EM; Caselli RJ
    J Clin Psychiatry; 2009 Oct; 70(10):1379-84. PubMed ID: 19573495
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of intranasal esketamine for the treatment of major depressive disorder.
    Kryst J; Kawalec P; Pilc A
    Expert Opin Pharmacother; 2020 Jan; 21(1):9-20. PubMed ID: 31663783
    [No Abstract]   [Full Text] [Related]  

  • 34. Brief Report: Intranasal Ketamine in Adolescents and Young Adults with Autism Spectrum Disorder-Initial Results of a Randomized, Controlled, Crossover, Pilot Study.
    Wink LK; Reisinger DL; Horn P; Shaffer RC; O'Brien K; Schmitt L; Dominick KR; Pedapati EV; Erickson CA
    J Autism Dev Disord; 2021 Apr; 51(4):1392-1399. PubMed ID: 32642957
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A single-center, randomized, double-blind, placebo-controlled, crossover investigation of the effects of fexofenadine hydrochloride 180 mg alone and with alcohol, with hydroxyzine hydrochloride 50 mg as a positive internal control, on aspects of cognitive and psychomotor function related to driving a car.
    Ridout F; Shamsi Z; Meadows R; Johnson S; Hindmarch I
    Clin Ther; 2003 May; 25(5):1518-38. PubMed ID: 12867226
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of DFN-11 (sumatriptan injection, 3 mg) in adults with episodic migraine: a multicenter, randomized, double-blind, placebo-controlled study.
    Landy S; Munjal S; Brand-Schieber E; Rapoport AM
    J Headache Pain; 2018 Aug; 19(1):69. PubMed ID: 30112726
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adjunctive intranasal esketamine for major depressive disorder: A systematic review of randomized double-blind controlled-placebo studies.
    Zheng W; Cai DB; Xiang YQ; Zheng W; Jiang WL; Sim K; Ungvari GS; Huang X; Huang XX; Ning YP; Xiang YT
    J Affect Disord; 2020 Mar; 265():63-70. PubMed ID: 31957693
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dose-Response of Paraxanthine on Cognitive Function: A Double Blind, Placebo Controlled, Crossover Trial.
    Xing D; Yoo C; Gonzalez D; Jenkins V; Nottingham K; Dickerson B; Leonard M; Ko J; Faries M; Kephart W; Purpura M; Jäger R; Wells SD; Sowinski R; Rasmussen CJ; Kreider RB
    Nutrients; 2021 Dec; 13(12):. PubMed ID: 34960030
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of adjunctive therapy using esketamine or racemic ketamine for adult treatment-resistant depression: A randomized, double-blind, non-inferiority study.
    Correia-Melo FS; Leal GC; Vieira F; Jesus-Nunes AP; Mello RP; Magnavita G; Caliman-Fontes AT; Echegaray MVF; Bandeira ID; Silva SS; Cavalcanti DE; Araújo-de-Freitas L; Sarin LM; Tuena MA; Nakahira C; Sampaio AS; Del-Porto JA; Turecki G; Loo C; Lacerda ALT; Quarantini LC
    J Affect Disord; 2020 Mar; 264():527-534. PubMed ID: 31786030
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.